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ABSTRACT 
The progression of prostate cancer (PC) to a metastatic hormone refractory disease is the major 
contributor to the overall cancer mortality in men, mainly because the conventional therapies are 
generally ineffective at this stage. Thus, other therapeutic options are needed as alternatives or in 
addition to the classic approaches to prevent or delay tumor progression. Catecholamines participate 
to the control of prostate cell functions by the activation of alpha1-adrenoreceptors (alpha1-AR) and 
increased sympathetic activity has been linked to PC development and evolution. Molecular and 
pharmacological studies identified three alpha1-AR subtypes (A, B and D), which differ in tissue 
distribution, cell signaling, pharmacology and physiological role. Within the prostate, alpha1A-ARs 
mainly control stromal cell functions, while alpha1B- and alpha1D- subtypes seem to modulate 
glandular epithelial cell growth. The possible direct contribution of alpha1D-ARs in tumor biology 
is supported by their overexpression in PC. The studies here presented investigate the "in vitro" 
antitumor action of A175, a selective alpha1D-AR antagonist we have recently obtained by 
modifying the potent, but not subtype-selective alpha1-AR antagonist (S)-WB4101, in the 
hormone-refractory PC3 and DU145 PC cell lines. The results indicate that A175 has an alpha1D-
AR-mediated significant and dose-dependent antiproliferative action that possibly involves the 
induction of G0/G1 cell cycle arrest, but not apoptosis. In addition, A175 reduces cell migration and 
adhesiveness to culture plates. In conclusion, our work clarified some cellular aspects promoted by 
alpha1D-AR activity modulation and supports a further pharmacological approach in the cure of 
hormone-refractory PC, by targeting specifically this AR subtype. 
 
KEYWORDS: adrenergic system, alpha1D-adrenoreceptor selective antagonist, hormone-resistant 
human prostate cancer, anticancer activity, "in vitro" cell proliferation, "in vitro" cell migration. 
CHEMICAL COMPOUNDS STUDIED IN THIS ARTICLE: Phenylephrine hydrochloride 
(PubChem CID: 5284443); phenoxybenzamine hydrochloride (PubChem CID: 5284441); docetaxel 
(PubChem CID: 148124). 
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1. INTRODUCTION  
Despite the intense basic and pharmacological research in these last years, prostate cancer (PC) is 
still a major contributor to the overall cancer mortality in men, because of tumor progression from 
an androgen-dependent to an androgen independent/castration resistant phenotype [1]. 
Conventional therapies for metastatic hormone-refractory PC are mostly palliative and fail to 
effectively improve the survival rate, at present [2]. Thus, further options are needed as alternatives 
or in addition to the classic therapeutic approaches to prevent or delay tumor growth, minimizing 
toxicity.  
Alpha1-adrenoreceptors (alpha1-AR), which have been subdivided into three pharmacologically 
distinct subtypes (alpha1A, alpha1B and alpha1D, [3]), mediate several of the actions exerted by 
catecholamines on prostate cells, including stroma and epithelial growth, as well as smooth muscle 
contraction [4]. Increased sympathetic activity has been linked to PC recurrence, progression and 
aggressiveness (see [5] for references). Moreover, similarly to angiogenesis, new autonomic nerve 
projections infiltrate the tumor mass, participating to cancer evolution and providing a gateway for 
cell dissemination (perineural invasion) [6].  
Studies on alpha1-AR subtype localization of within the human prostate reveal that alpha1A-ARs 
predominate in the stroma of the normal and hyperplastic glands [7, 8], where they are involved 
smooth muscle contraction. On the contrary, the presence of this AR subtype in the normal or 
neoplastic epithelial cells is still debated [9-14]. Alpha1B- and alpha1D-ARs localize almost 
exclusively in the epithelial compartment both of normal (PrEc) and neoplastic glands [7, 15], 
where they control cell growth [13]. Remarkably, alpha1D-ARs are overexpressed in androgen-
resistant PC cells [11] and in specimens from untreated patients with advanced PC [16].  
After being initially introduced for the management of hypertension, alpha1-AR antagonists have 
been successively targeted to the treatment of benign prostatic hyperplasia (BPH) and lower urinary 
tract symptoms (LUTS) [17]. The first observations on the antiproliferative effect of alpha1-AR 
antagonists in PC date back to early 2000, when quinazoline-based non subtype selective alpha1-
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AR blockers, such as prazosin, doxazosin and terazosin, were proved to stimulate PC cells 
apoptosis [9, 18-20]. In addition, retrospective clinical studies showed 30% decrease of the relative 
risk of PC development in patients treated with alpha1-AR blockers in comparison to untreated 
patients [21]. The possible additional use of alpha1-AR blockers in prostate related diseases was 
further promoted by the increasing availability of alpha1A/1D-AR and, more recently, alpha1D-AR 
selective antagonists with low alpha1B-AR affinity. Since alpha1B-ARs are highly expressed in 
human vascular bed and their expression increases with age [22], the use of selective alpha1B-AR 
blockers might develop undesirable side effects. On the contrary, the pharmacological profile of the 
alpha1A- and alpha1D-AR antagonists reveals slight effects on vascular resistance, particularly in 
elderly patients [23, 24].  
The recent intense research has clearly shown that PC growth is reduced both "in vitro" and "in 
vivo" by some alpha1A/D-AR antagonists (labedipinedilol-A, [25]), or slightly alpha1D- vs. 
alpha1A-AR antagonists (naftopidil [13, 26-28] and its very recent amide-indole derivatives [29]), 
or markedly alpha1D-AR antagonists (clopenphendioxan [11] and gem-diphenyl dioxane 
derivatives [30, 31]). On the other hand, very potent, but not subtype-specific alpha1-AR blockers, 
such as WB4101, or also other alpha1D-AR selective antagonists, such as BMY-7378, do not 
exhibit significant antiproliferative effect on PC cells [14, 30]. Also the correlation between alpha1-
AR antagonism and control of PC cells proliferation has not yet been completely elucidated and 
different action mechanisms have been demonstrated or suggested. The antiproliferative effect of 
naftopidil and of doxazosin seems to be alpha1-AR independent [9, 18-20, 28], while evidences 
have been provided that the antitumor activity is alpha1-AR mediated in the case of labedipinediol-
A [25] as well as of recently reported indolic analogues of naftopidil [29] and of the gem-
diphenyldioxane derivatives [30, 31]. 
On the basis that 1- not all the alpha1D-AR antagonists can suppress PC growth and 2- not all the 
antiproliferative alpha1D-AR antagonists have a receptor-mediated action, we undertook the 
present study on A175, a new potent and selective alpha1D-AR antagonist we recently discovered 
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through a long series of modifications of the well-known potent but not subtype selective alpha1-
AR antagonist 2-(2,6-dimethoxyphenoxyethylaminomethyl)-1,4-benzodioxane ((S)-WB4101 [32-
37]). The chemical structures of the two compounds are shown in the box below. A175 has 
alpha1D/alpha1A and alpha1D/alpha1B antagonist affinity ratios of 129 and 12, respectively, and is 
devoid of 5-HT1A and alpha2-AR affinity [37]. Aim of the investigation was, firstly, to asses 
whether this compound can effectively control "in vitro" cell proliferation, motility and survival of 
androgen-independent PC cells and, if so, to elucidate its action mechanism and the involvement of 
alpha1D-AR antagonism in these cellular responses. 
 
 
2. MATERIALS AND METHODS 
2.1 Cell cultures  
Human androgen independent prostate cancer PC3 and DU145 cell lines and the androgen-
dependent LNCaP cell line were originally obtained from American Type Culture Collection 
(ATCC, Rockville, MD, USA); CWR22Rv1 (Rv1) cells were originally obtained from Leibnitz-
Institut DSMZ (Braunschweig, Germany). All cell lines are currently used in our lab. The 
experiments were carried out between 30
th
  and 40
th
 in vitro passages.  
All cell culture reagents were purchased from EuroClone (Milan, Italy). LNCaP, Rv1, PC3 and 
DU145 cells were routinely grown at 37°C in a humidified atmosphere (5% CO2- 95% air) in 100 
mm Petri dishes in RPMI 1640 supplemented with 10% (PC3, LNCaP) or 5% (DU145, Rv1) heat 
inactivated fetal calf serum (FCS), glutamine (2 mM), penicillin (100 IU/mL), streptomycin (100 
μg/mL). Medium was changed biweekly.  
O
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Chemical structures of (S)-WB4101 and of its derivative A175 
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2.2 Chemicals and treatments 
A175 was prepared as previously reported [37], dissolved in water and added at the final 
concentrations reported in each figure. Phenylephrine hydrochloride, phenoxybenzamine 
hydrochloride and docetaxel (all from Aldrich Italia, Milan, Italy) were dissolved in water, in 
ethanol and in DMSO respectively. A175 (different doses) and phenylephrine (final concentration 
50 μM) treatments were carried out for 48 h. The irreversible alpha1-AR inhibitor 
phenoxybenzamine (final concentration 1 μM) was added to the cultures 4 h before adding A175.  
 
2.3 Growth rate evaluation 
PC3 and DU145 cells were seeded in 96-well plates (Greiner Bio-One; Frickenhausen, Germany) at 
a mean concentration of 5,000 cells/well in RPMI 1640 supplemented with 1% (basal conditions) or 
10% (serum-stimulated conditions) FCS, according to the different protocols (see the relative 
figures). All treatments were started 24 h after seeding. Cell proliferation was evaluated by 5-
bromo-2'-deoxyuridinee (BrdU) cell proliferation assay kit (Delfia, Perkin Elmer, Milan, Italy) 
according to manufacturer's protocol. Results, expressed as fluorescence emission/second 
(rlu/second), were obtained by determining the mean value of at least 6 independent 
samples/group/experiment.  
 
2.4 Cell toxicity and apoptosis  
Cytotoxicity of A175 was evaluated in two independent experiments by the CellTox Green 
Cytotoxicity Assay (Promega Italia, Milan, Italy), according to manufacturer's protocol. Briefly, 
PC3 cells were seeded in 96-well plates (4,500 cells/well) in RPMI containing either 1% or 10% 
FCS and treated with graded doses of A175 (least 8 wells/group) for 48 h. Untreated cell lysate was 
used as positive control of cytotoxicity. Cell fluorescence were measured in a MultiMode Plate 
Reader (EnSpire, Perkin Elmer, Milan, Italy). 
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Apoptosis activation by A175 was evaluated by a chemoluminescent assay (Caspase-Glo 3/7 Assay, 
Promega Italia, Milan, Italy), according to manufacturer's protocol. PC3 cells were plated in 96-
well plates (5,000 cell/well) and treated for 48 h with 25 or 50 μM A175 either in basal (1% FCS) 
or in serum-stimulated (10% FCS) conditions. The luminescent signal was measured in a 
luminescence counter (MicroBeta®, Perkin Elmer, Milan, Italy). Cells treated with Docetaxel 50 
nM for 48 or 72 h provided positive controls for apoptosis [38]. At least 8 wells/group in two 
independent experiments were used. 
 
2.5 Reverse transcriprion-real time PCR (qPCR) 
Total RNA from LNCaP, Rv1, PC3 and DU145 was extracted by the phenol-chloroform method 
according to standard protocols [39]. A mean of 2 independent RNA samples were used for each 
determination. Reverse transcription was performed on 1 μg of total RNA from each sample 
according to the manufacturer's protocol (iScript cDNA synthesis kit, BioRad, Segrate, Italy) using 
random primers. qPCR was done in singleplex in CFX96 Touch™ Real-Time PCR Detection 
System (BioRad, Segrate, Italy) by using SYBR Green dye (SsoAdvanced SYBR Green Supermix, 
Bio-Rad, Segrate, Italy). The specific set of primers are listed in Table 1. Data analysis was 
performed using the CFX Manager 2.0 software (Bio-Rad, Segrate, Italy). Each sample was 
analysed in triplicate. 
Table 1: primer sequences  
Target gene Forward primer Reverse primer 
alpha1A-AR AGTCATGCCCATTGGGTCTTT ATGGGGTTGATGCAGCTGTT 
alpha1B-AR CCTGAGGATCCATTCCAAGA CGGTAGAGCGATGAAGAAGG 
alpha1D-AR GTGCGCCACTCACTCAAGTA GAGCACACGGAGGAGAAGAC 
Beta-actin CCACCATGTACCCTGGCATT CGGACTCGTCATACTCCTGC 
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For each AR subtype the relative CT was normalized for beta-actin CT. Relative mRNA levels 
were then calculated by the comparative CT method (2
−ΔΔCt
) using as calibrator a sample of total 
RNA pooled from all PC cells [40]. 
 
2.6 Cell cycle analysis 
Flow cytometry was used to analyze cell cycle distribution. PC3 and DU145 cells were seeded in 30 
mm Petri dishes (150,000 cells/dish) in RPMI containing either 10% (PC3) or 5% (DU145) FCS 
and treated with graded doses of A175 (least 4 samples/group) for 48 h. After trypsinization, cells 
were resuspended in 0.5 ml of permeabilizing buffer of Sytox Dye (0.5 μM in 100 mM Tris, pH 7.4, 
150 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, and 0.1% Nonidet P-40). Samples were placed in the 
dark for 15 min, and the fluorescence of individual nuclei was measured. Nuclear Sytox Dye 
(Molecular Probe, Pittsburgh, PA) fluorescence signal was recorded on the FL2 channel of a 
FACScan flow cytometer (BD Biosciences, San Jose, CA) and analyzed with ModFit LT software 
(Verity Software House, Topsham, ME). The number of cells in G0/G1, S, and G2/M phases was 
expressed as percentages of total events (10,000 cells). 
 
2.7 Western blot analysis 
Control and treated cell lysates were prepared in RIPA buffer added with protease inhibitors. Equal 
amounts of total protein extracts (30 μg/sample), as determined by BCA method (Pierce, Rockford, 
IL, USA), were resolved on SDS-PAGE and electro-transferred to nitrocellulose membrane. 
Membranes were blocked with 5% non fat dry milk in tris-buffered saline for 1h before incubation 
overnight with the following primary antibodies: rabbit anti human p21 and p27 (1:750; Cell Cycle 
Regulation Sampler Kit, Cell Signaling Technology, EuroClone, Milan, Italy) and mouse anti 
human beta-actin (1:500; Abcam, Cambridge, UK). Immunoreactivity was detected by the 
fluorescent qDot system (Life Technologies Italia, Monza, Italy). Beta-actin was used to normalize 
target protein levels. Densitometric analysis of the fluorescent bands was performed using Image J 
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software. Four independent PC3 samples/group, obtained in two different experiments, were 
analyzed. 
 
2.8 Cell motility assay 
The influence of a 48 h treatment with A175 on PC3 and DU145 cell motility was evaluated in a 
Boyden chamber (Neuro Probe Inc., Gaithersburg, MD, USA) containing 8 μm 
polyvinylpyrrolidone-free polycarbonate filters precoated with gelatin (0.2 mg/mL in PBS) 5 day 
before and maintained at 4°C until use. After 48 h exposure to vehicle or A175 (10 or 50 μM) cells 
were harvested, counted, resuspended in DMEM + 0.1% BSA at the same concentration of 
2,000,000 cells/mL and plated in the upper compartment of the Boyden chamber (100,000 
cells/well). The lower compartment was filled either with DMEM or with DMEM+FCS 1% (28 
μL/well) to assess chemokinesis and chemotaxis respectively. After migration (overnight at 37°C), 
cells adherent to the lower membrane surface were fixed with methanol, stained according to the 
Diff-Quik kit (Biomap, Agrate, Italy) and counted in standard optical microscopy (40x). Three 
random objective fields of stained cells were counted for each well and the mean number of 
migrating cells/mm
2
 was calculated. The cell motility assay was repeated three times (at least 6 
independent sample/group/experiment).  
 
2.9 Cell adhesion assay 
After 48 h exposure to vehicle or A175 (10 or 50 μM) cells were collected, counted and seeded in 
24-well uncoated plates at the same concentration of 40,000 cells/well. Cells were allowed to attach 
to the plates during a 4 h incubation period at 37°C. After this period, non-attached cells were 
carefully washed away and the number of the remaining attached living cells was evaluated by 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric assay. Cell 
adhesion assay was repeated twice (8 independent sample/group/experiment). 
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2.10 Immunofluorescence and confocal laser scan microscopy 
Control and A175 treated PC3 cells, seeded on slides, were fixed in 4% paraformaldehyde in PBS 
for 10 min at room temperature and processed for alpha1D-AR immunostaining. Cells were  
permeabilized with Triton 0,3% in PBS (15 min, RT), blocked with 5% Normal Goat Serum in 
PBS/0.1% Tween-20 and incubated (4°C, overnight) with anti alpha1D-AR primary antibody (1:50, 
Santa Cruz Biotechnology, Heidelberg, Germany). Alexa Fluor 488 conjugate was used as 
secondary antibody (1:100, 1h, 37°C; Thermo Scientific, Rockford, IL, USA). After washing, slides 
were mounted using Vectashield
TM
 (Vector Laboratories, Burlingame, CA, USA). Control of the 
specificity of the antibody included a lack of primary antibody. Confocal microscopy was carried 
out using a Zeiss LSM 510 System (Gottingen, Germany) and images were processed with Image 
plus 6.0. 
 
2.11 Statistical analysis 
The statistical analysis of the row data was performed by one way ANOVA and expressed as mean 
± SD. Post-hoc analysis was performed by Tukey’s Multiple Comparison Test, using the Prism4 
software for Macintosh (GraphPad Software, San Diego, CA). Only p values <0.05 were considered 
statistically significant. The same software was used to calculate dose-response curves. 
 
3 RESULTS 
3.1 Expression of alpha1-AR subtypes  
The relative expression pattern of the three alpha1-AR subtypes in the main androgen-dependent 
(LNCaP), androgen-sensitive (Rv1) and androgen-independent (PC3, DU145) PC cell lines is 
shown in figure 1A. It appears that the alpha1A-AR subtype is present almost exclusively in the two 
cell lines that are still dependent/sensitive to androgens (Rv1 >> LNCaP), is lower in DU145 and 
absent in PC3 cells. Conversely, alpha1B- and alpha1D-AR subtypes seems to be present only in 
the two androgen-independent cell lines (alpha1B-AR DU145 >> PC3; alpha1D-AR confined in 
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PC3 cells). A second qPCR experiment limited to DU145 and PC3 cells better clarified the relative 
expression pattern of alpha1B-AR and alpha1D-AR subtypes in these two cell lines (figure 1B). In 
this case, RNA pooled only from PC3 and DU145 cells was used as calibrator. Also in this 
experiment it is clear that alpha1B-AR expression is 3 times higher in DU145 than in PC3 cells, 
while alpha1D-AR is expressed only in PC3 cells.  
 
3.2 Effects on PC cell proliferation 
The alpha1D-AR mediated antiproliferative action of A175 was assessed in PC3 cells both in basal 
(cells maintained in 1% FCS, figure 2A) or in growth-stimulating (cells maintained in 10% FCS, 
figure 2B) conditions. DU145 cells provided negative controls. As shown in figure 2A, a 48 h 
treatment with grading doses of A175 induces a progressive decrease of PC3 cell growth, which 
became highly significant from 10 μM onward. In the 10-75 μM interval each concentration is 
significantly more active that the previous one. The same significant inhibitory activity of 25 and 50 
μM A175 on PC3 cell growth is evident also in growth-stimulating conditions (figure 2B, left side). 
Conversely, A175 administered at the same concentration and treatment length is completely 
ineffective on DU145 cell growth (figure 2B, right side), suggesting that the antiproliferative action 
of A175 is alpha1D-AR mediated. A test performed in PC3 cells maintained either in 1% or in 10% 
FCS excluded a possible nonspecific cytotoxic effect of 48 h A175 exposure even at the dose of 75 
μM, which blocks almost completely cell proliferation (data not shown).  
To further assess the possible dependency of A175 action on alpha1D-AR binding, PC3 cells, 
maintained in 10% FCS medium, were stimulated to proliferate with phenylephrine (figure 3A) or 
were pretreated with the irreversible alpha1-AR antagonist phenoxybenzamine (figure 3B). As 
shown in the figure, the dose-dependent antiproliferative action of A175 alone in PC3 cell is 
apparent once again (left sides of panels A and B). As expected, phenylephrine stimulates cell 
proliferation, an effect that is significantly and dose-dependently counteracted by A175 (figure 3A, 
right side). From figure 3B (right side) it is apparent that PC3 pretreatment with phenoxybenzamine 
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(PBA) at the dose of 1 μM for 4 h does not influence cell growth; the exposure to PBA prior to the 
48 h treatment with A175 reduces, but does not completely block, the antigrowth action of the 
compound.  
Since A175 does not seem to induce caspase-associated apoptosis (not shown), we evaluated by 
FACScan analysis the effect of 48 h A175 exposure on PC3 and DU145 cell distribution along cell 
cycle (figure 4). Panels A and C report both the representative histograms of each experimental 
group and the cumulative results obtained in two independent experiments. The statistical analysis 
of the cumulative data  shows that A175 exposure progressively increases the amount of PC3 cells 
in the G0/G1 phase, with an effect that becomes significant at the higher dose (panel A). 
Conversely, no significant modifications were assessed in treated DU145 cells (panel C). In the 
same figure, panels B and D report a representative Western blot and the densitometric analysis of 
p21 and p27 levels in PC3 and DU145 cells respectively. The mean doubling of p27 and p21 levels 
in treated PC3 (panel B) but not in DU145 cells (panel D) strengthen the results obtained by 
FACScan analysis. 
 
3.3 Effects on PC cell motility and adhesion 
The ability of a 48 h treatment with A175 to modulate cell motility of PC3 and DU145 cells was 
investigated by microchemotaxis assay, evaluating, in separate experiments, either the spontaneous 
motility (chemokinesis) or the motility stimulated by a chemoattractant (FCS 1%). In this set of 
experiments A175 was used at the doses of 10 and 50 μM. As shown in figure 5, the presence of the 
chemoattractant increases the motility of both cell lines of about 5-6 times (DMEM vs FCS 1% 
control columns in panels A and B). Pretreatment with A175 neither at 10 nor at 50 μM is able to 
influence the spontaneous motility of PC3 and DU145 cells (data not shown); on the contrary, the 
two cell lines respond differently to the compound in chemotaxis experiments: PC3 cells show a 
highly significant and dose-dependent reduction of migration (figure 5A), while DU145 motility is 
unaffected (figure 5B).  
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A specific assay allowed identifying the effect A175 on the "in vitro" adhesion potential of PC3 
cells to uncoated culture plates. Figure 6 reports the percent of control and treated cells attached to 
the plate 4 h after re-seeding: cell attachment is significantly and dose-dependently reduced by a 
previous 48 h exposure to A175 at 10 and 50 μM (20% and 40% inhibition of cell attachment, 
respectively).  
 
3.4 Effects on alpha1D-AR cell localization 
The possible influence of A175 on alpha1D-AR localization within PC3 cells is shown in figure 7. 
Confocal analysis shows that in control cells alpha1D-AR is present in the nucleus and in small 
spots in the perinuclear region (*). After A175 treatment nuclear stain is maintained, while larger 
spots (more evident with the higher dose) appear in the whole cell body (**). 
 
4. DISCUSSION 
The relative expression pattern of alpha1-AR subtypes either in normal or in neoplastic human 
prostate is unclear from the literature, depending on the methods adopted (binding studies using 
high or low selective blockers, Western blots, immunohistochemistry, immunolocalization, etc.). To 
identify the best cell model to be used in our studies, we initially evaluated simultaneously the 
relative expression levels of the three alpha1-AR subtypes in the main androgen-sensitive or -
independent PC cell lines commercially available. According to some authors [9-12, 14], the major 
finding of our qPCR studies is that alpha1A-AR mRNA is present in less aggressive and still 
androgen sensitive PC cells (LNCaP and RV1), while it is absent, or present at lower levels, in the 
more aggressive androgen-independent DU145 and PC3 cells. Moreover, we demonstrate for the 
first time that this AR subtype is much more expressed in cells derived from a primary PC lesion 
(RV1) than in cells derived from metastatic sites (LNCaP and DU145), suggesting that selective 
alpha1A-AR blockers might be more useful to counteract cell proliferation in tissue-confined than 
in metastatic PC. In general agreement with the literature [11, 12, 41], our results also demonstrate 
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that alpha1B- and alpha1D-AR subtypes are expressed only in the androgen-independent PC cells, 
but with a different distribution: alpha1B-AR RNA appears almost exclusively in DU145, while 
alpha1D-AR is confined in PC3 cells. It should be underlined, however, that the presence of 
alpha1D-AR only in one of the PC cell lines tested does not ruled out its involvement in PC 
biology. Indeed, the overexpression of alpha1D-AR in many specimens from untreated patients 
with advanced PC [16] proves that this AR subtype is a valid target for PC treatment. As PC3 are 
the only PC cells expressing alpha1D-AR, we selected this cell line to evaluate specifically A175 
action.  
When PC3 cells have been maintained in basal proliferative conditions (FCS 1%), A175 dose-
dependently reduced cell growth, with a calculated IC50 of 19 μM. As expected, the 
antiproliferative action of the compound in PC3 cells maintained in growth-stimulating conditions 
(FCS 10%) is still dose-dependent, but less effective, with a mean reduction of cell proliferation of 
18 and 37% at doses of 25 and 50 μM, respectively. In these culture conditions, A175 seems to 
have a reduced potency compared to less specific alpha1-AR antagonists [9, 27] or to other 
selective alpha1D-AR blockers [11, 29], the IC50 of which ranges from 2 to 30 μM. However, 
doxazosin, terazosin, as well as naftopidil and its related compounds, reduce the growth rate also of 
DU145 and LNCaP cells [26, 27, 29], which, as previously discussed, lack alpha1D-ARs. It might 
be possible that all these compounds act either by interacting with other AR subtypes, or through an 
AR-independent mechanism, as suggested by many authors [9, 18, 25, 28]. 
The same A175 concentrations that significantly and dose-dependently reduce PC3 proliferation are 
completely unable to influence DU145 cell growth. As, in our hands, these cells are devoid of 
alpha1D-AR, this suggests that, as opposed to the other compounds, the antiproliferative activity of 
A175 is alpha1D-AR-mediated. The selective efficacy of A175 only in cells expressing alpha1D-
AR might be particularly important in light of the high intrinsic activity typical of this AR subtype 
demonstrated in other experimental models [42].  
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Similar to noradrenaline [11, 25], the alpha1-AR agonist phenylephrine (Phe) has a direct mitogenic 
effect on PC3 growth (about 130% over controls). A175 dose-dependently inhibits Phe-stimulated 
cell proliferation, supporting the alpha1D-AR-mediated action of the compound. To further confirm 
this issue, we pretreated PC3 cells with the irreversible inhibitor phenoxybenzamine (PBA). The 
exposure to PBA, which does not affect cell proliferation when given alone, slightly counteracts the 
antiproliferative action of A175. However, it should be underlined that in PBA pretreated cells 
A175, at both doses, is less effective in comparison to cells not previously exposed to the inhibitor 
(proliferation rate in plus vs minus PBA are 16% vs 20.1% and 26.7% vs 37.5% for A175 25 and 
50 μM respectively) and looses the dose-response effect. Similarly to our findings, PBA 
pretreatment also fails to fully counteract the action of other alpha1-AR blockers when given at 
concentrations higher than 10 μM [9, 25]. Hence, it is possible either that other pretreatment 
conditions (higher PBA concentrations and/or longer pretreatments) would give different results, or 
that at least part of A175 action on cell proliferation does not involve alpha1D-AR binding.  
As opposed to other alpha1-AR antagonists [9, 25, 29], A175 is completely unable to induce 
apoptosis of PC3 cells maintained either in basal (RPMI 1% FCS) or in growth-stimulated (RPMI 
10%FCS) conditions (data not shown). Thus, we evaluated whether, as already demonstrated for 
naftopidil [14, 26], the antiproliferative action of A175 might involve the modulation of cell cycle 
progression. FACScan analysis demonstrates that only in PC3 A175 exposure specifically induces a 
progressive increase of cell amount in the G0/G1 phase associated with increased levels of p27 and 
p21 (two inhibitors of cell cycle progression). Among senescence-associated cell cycle inhibitors, 
p27 and p21 are deeply involved in prostate growth, so that high p27 and/or p21 levels are 
independent predictors of favorable prognosis and increased survival in PC patients [43], while 
their downregulation is typical of high-grade/poor responsive PC [44]. A p21-dependent induction 
of PC3 senescence has been recently demonstrated as a mechanism of action of other drugs [45] 
and might account for the above discussed low activity of A175 compared to other pro-apoptotic 
alpha1-AR antagonists. The cytostatic property of A175 in cells that, as PC3, lack p53 is significant 
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since, in the absence of p53-mediated apoptosis, the activation of cellular senescence can still 
prevent genomic instability [46]. Cell cycle inhibition and/or the enhancement of senescence might 
be considered an effective chemopreventive strategy to reduce tumor growth and to decrease the 
risk of further genetic changes.  
Given that active migration and the ability to adhere to host tissues are critical determinants for 
metastasis development and that norepinephrine is a potent inducer of cancer cell migration [47], 
we tested the ability of A175 to interfere with PC3 chemotaxis and with the cell adhesion 
properties. A175 has a powerful antimigratory effect (reduction of cell motility of about 53% and 
70% at doses of 10 and 50 μM, respectively), which is already evident at concentrations ineffective 
on cell proliferation. Our preliminary experiments also demonstrate that PC3 exposure to A175 at 
the same concentrations significantly reduces cell ability to adhere to a new plate. A huge rise of 
p21 and p27 in normal mesenchymal cells loosing their anchorage has been recently described [48]. 
It is thus possible that hindering cell mitosis, by increasing p21 and p27, might prevent further cell 
anchorage by reducing cell adhesion proteins. Studies are ongoing to test this possibility. 
Quinazoline-based compounds significantly reduce cell motility [49] and adhesion [50, 51] with an 
action mechanism independent of alpha1-AR activation [49]. Conversely, the lack of efficacy of 
A175 on DU145 migration is indicative of an alpha1D-AR mediated effect. The induction of 
senescence and the antimigratory potential of alpha1D-AR selective antagonists, which minimize 
the metastatic behavior of PC cells, represent important chemopreventive aspects that deserves a 
more thoroughly evaluation in forthcoming studies. 
The multifaceted efficacy of the compound also in the absence of a stimulating effect by 
catecholamines suggests that A175 might behave as an inverse agonist of a receptor endowed with 
constitutive activity [3]; this action appears to be different from the neutral antagonist behavior we 
previously observed for this molecule in other functional tests [34]. As alpha1D-ARs display a 
prevalent intracellular localization [3, 11, 42, 52], we wondered whether the effect of A175 might 
be related to modification of receptor trafficking among cell compartments. Confocal microscopy 
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shows that, as expected, alpha1D-AR appears in small clusters (cytoplasmic vesicles?) in a 
prevalent perinuclear localization. After 48 h of exposure to the compound the receptors appear to 
be clustered in significantly larger immunoreactive spots scattered in all cell body. As opposed to 
what demonstrated for other inverse agonists [53], A175 does not seem to influence the 
redistribution of the receptor from cytoplasm to cell membrane. Our confocal results do not allow to 
speculate on the cellular pathway(s) activated by A175/alpha1D-AR complex, at present. The 
mechanism of action of alpha1D-AR in the control of cell proliferation is still elusive, involving 
either the formation of homo/heterodimers [54], or the crosstalk with other membrane proteins, 
such as calcium channels [16]. As the majority of the studies on the relationship between alpha1D-
AR activity and its cell localization have been conducted in transfected in vitro models [3, 52, 53], 
further studies should be undertaken to elucidate the functional role of the endogenous receptor and 
the mechanism(s) through which selective antagonists counteract its activity. 
 
5. CONCLUSIONS 
Overall, the data obtained strongly support the efficacy of A175 as cytostatic agent, able to reduce 
cell proliferation interfering with cell cycle progression, to decrease cell motility and to reduce cell 
adhesion. The inefficacy of the compound in cells lacking alpha1D-AR, as DU145, support the 
notion that cell response to A175 is mainly receptor-mediated.  
Considerable pharmacological efforts have been recently directed toward molecules able to 
specifically target PC growth and progression, in the attempt to improve chemoprevention and 
therapeutic response, minimizing toxicity. The studies here presented support a new 
pharmacological approach for the cure of androgen-independent highly metastatic PC by targeting 
alpha1D-ARs and suggest that A175 may represent a promising lead compound to design new more 
potent selective ligands. Further studies need to be done to confirm the anticancer capability of this 
or other selective alpha1D-AR blockers also in vivo. Moreover, as the ability to prevent PC 
development in xenograft models [50] and to decrease the incidence of PC in men [21] has been 
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demonstrated for alpha1-AR antagonists, future studies should focus on the possible prophylactic 
value of A175 and/or other selective alpha1D-AR blockers in PC chemoprevention.  
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LEGEND TO FIGURES 
 
Figure 1: relative expression levels of the three main alpha1-AR in different human prostate cancer 
cell lines.  
Panel A: relative expression of alpha1A-AR, alpha1B-AR and alpha1D-AR in LNCaP, Rv1, 
PC3 and DU145 cells. The expression level of each AR subtype has been quantified by the 
2
−ΔΔCt
 method using RNA pooled from all PC cells as calibrator. Panel B: relative expression of 
alpha1B-AR and alpha1D-AR in PC3 and DU145 cells. The expression level of each AR 
subtype has been quantified by the 2
−ΔΔCt
 method using total RNA pooled from PC3 and DU145 
cells as calibrator.   
 
Figure 2: Inhibitory action of A175 on androgen-independent PC cell proliferation. 
Cell proliferation has been evaluated by BrdU incorporation into DNA. Data are expressed as 
mean±SD of adsorbance at 450 nm (rlu/sec).
  
Panel A: PC3 cells maintained in starved 
conditions (FCS 1%,) exposed to graded A175 concentrations (1-75 μM) for 48 hours. *p< 0,01 
vs control cells (CRL); 
**
p< 0.001 vs CRL or vs all the lower A175 concentrations. Panel B: 
PC3 and DU145 cells maintained in growth stimulating conditions (FCS 10%) exposed to 
different A175 concentrations (25 and 50 μM) for 48 hours. *p< 0.05 vs control cells (CRL); 
**
p< 0.001 vs CRL; 
§
p< 0.05 vs A175 25 μM. 
 
Figure 3: Inhibitory action of A175 on PC3 cell growth in presence of phenylephrine (Phe) or 
phenoxybenzamine (PBA). 
Cell proliferation has been evaluated by BrdU incorporation into DNA after a 48 h exposure to 
A175. Data are expressed as mean±SD of adsorbance at 450 nm (rlu/sec). Panel A: Cells 
maintained in FCS 10% were treated with A175 25 or 50 μM with or without phenylephrine 50 
μM. Panel B: Cells maintained in FCS 10% were exposed to vehicle (left side) or to 
 26 
phenoxybenzamine 1 μM (right side) 4 h prior to the addition of A175 25 or 50 μM. ap< 0.05 vs 
the respective untreated controls; 
b
p< 0.001 vs the respective untreated controls;
 c
p< 0.001 vs 
A175 25 μM; dp< 0.01 vs Phe 50 μM; ep< 0.001 vs Phe 50 μM;  fp< 0.001 vs Phe 50 μM+A175 
25 μM; gp< 0.05 vs A175 25 μM w/o PBA. 
 
Figure 4: Cell cycle analysis and p27 and p21 levels in PC3 and DU145 cells exposed to A175.  
Panel A: representative histograms of each experimental group and cumulative results of the % 
distribution along cell cycle in PC3 cells; **p<0.01 vs controls (CRL). Panel C: representative 
histograms of each experimental group and cumulative results of the % distribution along cell 
cycle in DU145 cells. Panel B: representative Western blot of p27 and p21 levels in PC3 cells 
and densitometric analysis of all the samples analyzed. Data are expressed as mean % variation ± 
SD of relative optic densities (MOD), normalized for beta-actin, vs controls. Panel D: 
representative Western blot of p27 and p21 levels in DU145 cells and corresponding 
densitometric analysis. Data are expressed as % variation of relative optic densities (MOD), 
normalized for beta-actin, vs controls.  
  
Figure 5: Effect of A175 on PC3 and DU145 cell motility. 
PC3 (panel A) and DU145 (panel B) cells were treated with A175 10 or 50 μM for 48 h and 
than used to evaluate microchemotaxis in presence of FCS 1% as chemoattractant (Boyden's 
chamber assay, overnight migration at 37C°). Untreated cells in presence of DMEM represent 
the spontaneous chemokinetic activity. Data are expressed as mean±SD of the number of 
migrated cells/mm
2
.**p< 0.001 vs control cells (FCS 1% CTR). 
 
Figure 6: Effect of A175 on PC3 cell attachment on uncoated Petri dishes.  
 27 
PC3 cells were exposed to A175 10 or 50 μM for 48 h, harvested and seeded at the same density 
on uncoated new culture plates. After 4 h incubation, the number of attached cells was assessed 
by MTT assay. The data are expressed as mean±SD % of treated vs control cells (CTR). 
**
p< 
0.001 vs CTR; 
§§
p< 0.001 vs A175 10 μM. 
 
Figure 7: immunofluorescence and confocal microscopy of alpha1D-AR in PC3 cells exposed to 
25 or 50 μM A175, for 48 h.  
Alpha1D-AR immunopositivity is localized in small spots in the nucleus and in the perinuclear 
region (*) in control cells and in larger spots in the whole cell body (**) in A175 exposed cells. 
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